Clinical trial
Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the…
NCT00186498 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00186498 |
|---|---|
| Title | Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression |
| Official title | Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Severe Major Depressive Episode |
| Lead sponsor | Stanford University, Other |
| Collaborators | Forest Laboratories Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major |
| Intervention type | Drug |
| Interventions | memantine, Placebo Oral Capsule |
| Enrollment | 11 |
| Start date | Feb 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Sep 27, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: